MED21

Across TCGA pan-cancer cohorts, MED21 mass-spec protein differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of MED21’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where MED21 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types MED21 is over-expressed in tumor, although a few such as HNSC and PDAC show the opposite, repressed pattern.

CCRCC, COAD, and HNSC are the cancer types where MED21 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in MED21 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	All	All	+0.153	<.001	9	view →
COAD	Female	III,IV	+0.298	<.001	8	view →
HNSC	All	IV	−0.302	.029	4	view →
PDAC	All	All	−0.219	.009	4	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 4 strongest of 4 lineages.

MED21–CCRCC

Open the CCRCC breakdown →